TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23998235

Group type: EXPERIMENTAL
Intervention: IL-2 levels in exhaled breath condensates (EBC) in asthmatic patients
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: IL-10 levels in exhaled breath condensates (EBC) in asthmatic patients
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: ACT score in asthmatic patients
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Percent predicted FEV1 in asthmatic patients
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: IL-2 levels in EBC in obese subjects
Number of subjects: 28

Group type: COMPARATOR
Intervention: IL-2 and IL-10 levels in EBC in healthy volunteers (control)
Number of subjects: 28
Study: 23999023

Group type: EXPERIMENTAL
Intervention: Structured interview and comprehensive assessment in stroke patients at risk of VCI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New standardized evaluation battery of clinical, cognitive, behavioral and neuroradiological data
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Comprehensive assessment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Use of structured interview
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recent techniques for analysis of MRI data
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amyloid PET imaging
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment of modifiable vascular risk factors and secondary prevention of stroke recurrence
Number of subjects: 0
Study: 24001117

Group type: EXPERIMENTAL
Intervention: Current triptan users
Number of subjects: 276

Group type: COMPARATOR
Intervention: Discontinued triptan users
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Lack of efficacy
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: MIDAS > 24
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: BDI > 4
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: History of opioid use
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Triptan prescribed by a specialist
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Using at least 1 other abortive medication with triptan
Number of subjects: 276
Study: 24001465

Group type: EXPERIMENTAL
Intervention: Surgical Assessment Unit (SAU)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Emergency Department (ED)
Number of subjects: 109
Study: 24001533

Group type: EXPERIMENTAL
Intervention: 2.0 mg ranibizumab
Number of subjects: 0
Study: 24001532

Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 24002003

Group type: EXPERIMENTAL
Intervention: MediGuide Technology (MGT) for CRT implantation
Number of subjects: 15
Study: 24002394

Group type: EXPERIMENTAL
Intervention: Fluid balance (FB)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Serum creatinine (SCr)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Urine NGAL
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: IL-18
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Serum MCP-1
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: TNF-alpha
Number of subjects: 100
Study: 24002496

Group type: EXPERIMENTAL
Intervention: Quizartinib administered orally at escalating doses of 12 to 450 mg/day
Number of subjects: 76
Study: 24002500

Group type: EXPERIMENTAL
Intervention: Lenalidomide 25 mg orally on days 1 through 21 every 28 days until disease progression or intolerance
Number of subjects: 134
Study: 24003046

Group type: EXPERIMENTAL
Intervention: Systematic cerebral MRI
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Vegetation length >4 mm
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Staphylococcus aureus IE
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Prosthetic IE
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Vegetation length (1 mm increase)
Number of subjects: 120
Study: 24003088

Group type: EXPERIMENTAL
Intervention: Toric orthokeratology (ortho-k)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study: 24004118

Group type: EXPERIMENTAL
Intervention: Low-dose CT screening in the PanCan cohort
Number of subjects: 2961

Group type: EXPERIMENTAL
Intervention: Low-dose CT screening in the BCCA cohort
Number of subjects: 2961

Group type: EXPERIMENTAL
Intervention: Predictive tools based on patient and nodule characteristics
Number of subjects: 2961
Study: 24004540

Group type: EXPERIMENTAL
Intervention: Twice-daily Ropinirole prolonged release (RPR)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Once-daily Ropinirole prolonged release (RPR)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Both regimens (once-daily and twice-daily RPR)
Number of subjects: 82
Study: 24004642

Group type: EXPERIMENTAL
Intervention: DAPT interruption
Number of subjects: 5018

Group type: EXPERIMENTAL
Intervention: DAPT disruption
Number of subjects: 5018

Group type: EXPERIMENTAL
Intervention: DAPT cessation (overall)
Number of subjects: 5018

Group type: EXPERIMENTAL
Intervention: DAPT discontinuation
Number of subjects: 5018

Group type: EXPERIMENTAL
Intervention: DAPT disruption within 7 days
Number of subjects: 5018

Group type: EXPERIMENTAL
Intervention: DAPT disruption 8-30 days
Number of subjects: 5018

Group type: EXPERIMENTAL
Intervention: DAPT disruption more than 30 days
Number of subjects: 5018
Study: 24004667

Group type: EXPERIMENTAL
Intervention: Bortezomib, dexamethasone, and rituximab (BDR) combination therapy
Number of subjects: 59
Study: 24004934

Group type: EXPERIMENTAL
Intervention: Low sodium (51.3 mmol/day)
Number of subjects: 695

Group type: EXPERIMENTAL
Intervention: High sodium (307.8 mmol/day)
Number of subjects: 695

Group type: EXPERIMENTAL
Intervention: High sodium with potassium supplementation (307.8 mmol sodium and 60 mmol potassium/day)
Number of subjects: 695

Group type: EXPERIMENTAL
Intervention: Cold pressor test (CPT)
Number of subjects: 695
Study: 24005614

Group type: EXPERIMENTAL
Intervention: Sorafenib at a dose of 800 mg daily
Number of subjects: 5
Study: 24005640

Group type: EXPERIMENTAL
Intervention: Prehospital mortality
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: In-hospital mortality
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Overall mortality
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Median survival time
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Determinants of prehospital mortality
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Determinants of in-hospital mortality
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Multivariate model significant determinants of mortality
Number of subjects: 85
Study: 24006858

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) at a dosage of 40 ppm
Number of subjects: 16
Study: 24007627

Group type: EXPERIMENTAL
Intervention: Cisplatin and vinorelbine
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: miRNA signature (miR-149 and miR-375)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Prognostic score including miR-200c, miR-424, miR-29c, and miR-124
Number of subjects: 38
Study: 24007746

Group type: EXPERIMENTAL
Intervention: Docetaxel 75 mg/m², Cyclophosphamide 600 mg/m², Trastuzumab 4 mg/kg (loading dose) on day 1 and 2 mg/kg on days 1, 8, and 15 during chemotherapy, followed by Trastuzumab 6 mg/kg every three weeks for 1 year.
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: Docetaxel and Cyclophosphamide combined with Trastuzumab
Number of subjects: 493
Study: 24007819

Group type: EXPERIMENTAL
Intervention: Bevacizumab (7.5mg/kg, day 1), weekly paclitaxel (80 mg/m(2) days 1, 8, 15), and carboplatin (AUC6, day 1) intravenously q3w for 6-8 cycles, followed by single-agent bevacizumab for 1 year.
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Bevacizumab-containing regimen
Number of subjects: 189
Study: 24007969

Group type: EXPERIMENTAL
Intervention: Tryton Side Branch Stent
Number of subjects: 252
Study: 24008570

Group type: EXPERIMENTAL
Intervention: Statin use in hypercholesterolemia (HC)
Number of subjects: 558

Group type: COMPARATOR
Intervention: Hypercholesterolemia without statin use
Number of subjects: 558

Group type: COMPARATOR
Intervention: Normocholesterolemia
Number of subjects: 558
Study: 24008739

Group type: EXPERIMENTAL
Intervention: PCV13 (1 dose)
Number of subjects: 74
Study: 24008868

Group type: EXPERIMENTAL
Intervention: 25-hydroxyvitamin D deficiency (< 20 ng/dL)
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Desirable concentrations (> 30 ng/dL)
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Vitamin D supplements
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: 25-hydroxyvitamin D concentration
Number of subjects: 356
Study: 24009136

Group type: EXPERIMENTAL
Intervention: ¹²³I-IBZM SPECT
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: D2DR expression
Number of subjects: 10
Study: 24009220

Group type: EXPERIMENTAL
Intervention: ACTH gel (80 units injected subcutaneously twice weekly)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: ACTH gel
Number of subjects: 24
Study: 24009246

Group type: EXPERIMENTAL
Intervention: Surgical stress response
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Burn injuries
Number of subjects: 0
Study: 24009417

Group type: EXPERIMENTAL
Intervention: Long-term application of noninvasive ventilation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 24010976

Group type: EXPERIMENTAL
Intervention: Baseline pulsatility index (PI) ≤ 0.80
Number of subjects: 53

Group type: COMPARATOR
Intervention: Baseline pulsatility index (PI) > 0.80
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Patients with cognitive improvement
Number of subjects: 53

Group type: COMPARATOR
Intervention: Patients without cognitive improvement
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Baseline PI ≤ 0.80
Number of subjects: 53
Study: 24011220

Group type: EXPERIMENTAL
Intervention: Digital diary (DiD)
Number of subjects: 700

Group type: COMPARATOR
Intervention: Paper diary (PD)
Number of subjects: 700
Study: 24013510

Group type: EXPERIMENTAL
Intervention: Lapatinib and capecitabine (first-line combination treatment)
Number of subjects: 44
Study: 24013578

Group type: EXPERIMENTAL
Intervention: Extraction of retinal tacks using custom-built titanium alloy tacks, mechanically removed after prolonged implantation (up to 19 months).
Number of subjects: 4
Study: 24013904

Group type: EXPERIMENTAL
Intervention: Capecitabine 650 mg/m(2) twice daily and everolimus 5 mg twice daily
Number of subjects: 47
Study: 24014245

Group type: EXPERIMENTAL
Intervention: Carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) at maximum planned dose (MPD)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) in bortezomib-refractory patients
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) in lenalidomide-refractory patients
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) at MPD
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Adverse events (AEs) related to CRd
Number of subjects: 52
Study: 24014509

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 24014659

Group type: EXPERIMENTAL
Intervention: Dietary pulses
Number of subjects: 554
Study: 24014882

Group type: COMPARATOR
Intervention: Control arm (n = 2926)
Number of subjects: 5838
Study: 24015953

Group type: EXPERIMENTAL
Intervention: 8 mg of dexamethasone in 2 ml saline (treatment group)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Saline alone (placebo group)
Number of subjects: 152
Study: 24016493

Group type: EXPERIMENTAL
Intervention: Patients with CKD and CAD
Number of subjects: 3300

Group type: EXPERIMENTAL
Intervention: Follow-up assessments at 6, 12, 24, 36, 48, and 60 months
Number of subjects: 3300
Study: 24018147

Group type: EXPERIMENTAL
Intervention: Laparoscopic ultrasound-guided RFVTA
Number of subjects: 135
Study: 24018545

Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24018835

Group type: EXPERIMENTAL
Intervention: Exenatide BID
Number of subjects: 2515

Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 2515
Study: 24019004

Group type: EXPERIMENTAL
Intervention: Verified spider bites (Cheiracanthium punctorium, Zoropsis spinimana, Amaurobius ferox, Tegenaria atrica, Malthonica ferruginea)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Cheiracanthium punctorium
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: General spider bites in Switzerland
Number of subjects: 19
Study: 24019130

Group type: EXPERIMENTAL
Intervention: Audit study
Number of subjects: 12134

Group type: EXPERIMENTAL
Intervention: Audit study without patient feedback
Number of subjects: 12134
Study: 24019244

Group type: EXPERIMENTAL
Intervention: FeNO >15.8 ppb
Number of subjects: 3612

Group type: EXPERIMENTAL
Intervention: Rint >175.4%
Number of subjects: 3612

Group type: EXPERIMENTAL
Intervention: Lung function parameters and FeNO interpretation
Number of subjects: 3612
Study: 24019397

Group type: EXPERIMENTAL
Intervention: CYP2C19 poor metabolizer in patients with AMI
Number of subjects: 2188

Group type: COMPARATOR
Intervention: CYP2C19 extensive metabolizer in patients with AMI
Number of subjects: 2188

Group type: EXPERIMENTAL
Intervention: CYP2C19 poor metabolizer in patients with stable angina
Number of subjects: 2188

Group type: EXPERIMENTAL
Intervention: CYP2C19 intermediate metabolizer in patients with AMI
Number of subjects: 2188

Group type: COMPARATOR
Intervention: CYP2C19 extensive metabolizer in patients with stable angina
Number of subjects: 2188
Study: 24019544

Group type: EXPERIMENTAL
Intervention: Panobinostat 20 mg plus bortezomib 1.3 mg/m(2) (MTD) in the escalation phase
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Panobinostat plus bortezomib with dexamethasone in the expansion phase
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Panobinostat plus bortezomib in the escalation phase
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Panobinostat plus bortezomib in the expansion phase
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Panobinostat plus bortezomib in bortezomib-refractory patients
Number of subjects: 62
Study: 24021693

Group type: EXPERIMENTAL
Intervention: cCTA-guided triage
Number of subjects: 368

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 368
Study: 24021766

Group type: EXPERIMENTAL
Intervention: Engager transapical valve system
Number of subjects: 61
Study: 24021910

Group type: EXPERIMENTAL
Intervention: LUS-guided radiofrequency volumetric thermal ablation
Number of subjects: 135

Group type: COMPARATOR
Intervention: Site CE-MRI
Number of subjects: 135

Group type: COMPARATOR
Intervention: Central reader CE-MRI
Number of subjects: 135

Group type: COMPARATOR
Intervention: TVUS
Number of subjects: 135
Study: 24022390

Group type: COMPARATOR
Intervention: Gabapentin 900 mg daily in three divided doses (control)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Standardised hypnotherapy
Number of subjects: 15
Study: 24022986

Group type: EXPERIMENTAL
Intervention: Gray-scale (GS) and power Doppler (PD) ultrasound
Number of subjects: 49

Group type: COMPARATOR
Intervention: Clinical examination
Number of subjects: 49
Study: 24023466

Group type: EXPERIMENTAL
Intervention: Omega-3 supplementation (2 g/day)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 70
Study: 24023652

Group type: EXPERIMENTAL
Intervention: Insulin infusion test
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Insulin infusion test in patients with good hypoglycaemia awareness
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Insulin infusion test in patients with poor hypoglycaemia awareness
Number of subjects: 17
Study: 24023791

Group type: EXPERIMENTAL
Intervention: HRP2 based rapid diagnostic test (RDT)
Number of subjects: 3890
Study: 24024534

Group type: EXPERIMENTAL
Intervention: Quetiapine (flexibly dosed at 400-800 mg/day, with options to reduce to 200 mg/day based on tolerability)
Number of subjects: 381
Study: 24025234

Group type: EXPERIMENTAL
Intervention: IntelliVent-ASV™
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: IntelliVent-ASV™ in passive patients
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: IntelliVent-ASV™ in passive ARDS patients
Number of subjects: 100
Study: 24025627

Group type: EXPERIMENTAL
Intervention: PAV-TAS2R38 mRNA expression
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control solutions (carrot juice, NaCl, caffeine, urea)
Number of subjects: 22
Study: 24025631

Group type: EXPERIMENTAL
Intervention: Potassium excretion measurement
Number of subjects: 1656

Group type: EXPERIMENTAL
Intervention: Self-reported fruit and vegetable intake
Number of subjects: 1656

Group type: COMPARATOR
Intervention: Comparison of potassium excretion by race
Number of subjects: 1656

Group type: COMPARATOR
Intervention: Comparison of potassium excretion by education level
Number of subjects: 1656

Group type: COMPARATOR
Intervention: Comparison of potassium excretion by income level
Number of subjects: 1656

Group type: COMPARATOR
Intervention: Access to fresh produce
Number of subjects: 1656
Study: 24025700

Group type: EXPERIMENTAL
Intervention: Ipilimumab and vemurafenib
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: High-dose steroids
Number of subjects: 1
Study: 24027187

Group type: EXPERIMENTAL
Intervention: Maternal phenotype and diet
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Milk oligosaccharide concentration
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Total concentration of milk oligosaccharides
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Exploration of interrelations between milk sugars
Number of subjects: 52
Study: 24028306

Group type: EXPERIMENTAL
Intervention: Intervention: Intensification of lifestyle changes and sequential prescription of antihypertensive drugs (diuretic, ACE inhibitors, β-adrenergic blocking agent, calcium channel blocking agent) if BP >130/80 mmHg.
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Intervention: Intensification of lifestyle changes and sequential prescription of antihypertensive drugs.
Number of subjects: 78
Study: 24028564

Group type: EXPERIMENTAL
Intervention: Restrictive TV parenting practices
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: PA logistic support parenting practices
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Increased availability of screen-media equipment in the child's bedroom
Number of subjects: 83
Study: 24028677

Group type: EXPERIMENTAL
Intervention: Omalizumab (75 or 150 mg in a pre-filled syringe) at 2 or 4 week intervals for 24 weeks
Number of subjects: 155
Study: 24028745

Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Whole sample
Number of subjects: 371
Study: 24028749

Group type: EXPERIMENTAL
Intervention: Etonogestrel contraceptive implant placed within 15 min of mifepristone administration
Number of subjects: 20
Study: 24029408

Group type: EXPERIMENTAL
Intervention: Pf p52(-)/p36(-) GAP sporozoites via infected Anopheles mosquito bite (5-bite exposure followed by 200-bite exposure)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Pf p52(-)/p36(-) GAP sporozoites
Number of subjects: 6
Study: 24030098

Group type: EXPERIMENTAL
Intervention: Lenalidomide 25 mg daily on days 1-21 every 28 days until progressive disease or intolerability
Number of subjects: 57
Study: 24030379

Group type: EXPERIMENTAL
Intervention: Donor-derived CD19.CAR virus-specific T cells (CD19.CAR-VSTs)
Number of subjects: 8
Study: 24030617

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 24030685

Group type: EXPERIMENTAL
Intervention: Milnacipran 100 mg/day
Number of subjects: 45
Study: 24030879

Group type: EXPERIMENTAL
Intervention: IPTp with sulfadoxine/pyrimethamine (SP) given twice during pregnancy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ITNs alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined intervention with both ITNs and IPTp-SP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness of IPTp-SP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness of ITNs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness of combined intervention IPTp-SP + ITNs
Number of subjects: 0
Study: 24030917

Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg
Number of subjects: 30
Study: 24030918

Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin (PLD) 30 or 40 mg/m² intravenously on day 1; dexamethasone 40 mg orally on days 1-4; lenalidomide 25 mg orally on days 1-21, administered every 28 days
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Induction therapy
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Maintenance therapy with lenalidomide
Number of subjects: 57
Study: 24030928

Group type: EXPERIMENTAL
Intervention: Cyclosporine (CsA) with protease inhibitors (PIs)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Cyclosporine (CsA) with efavirenz (EFV)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Tacrolimus (TAC) with efavirenz (EFV)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Cyclosporine (CsA) with nevirapine (NVP)
Number of subjects: 52
Study: 24032456

Group type: EXPERIMENTAL
Intervention: Ofatumumab 300 mg IV on Day 1, followed by seven weekly IV infusions of 1000 mg.
Number of subjects: 81
Study: 24033249

Group type: EXPERIMENTAL
Intervention: Self-reported sleep problems
Number of subjects: 314
Study: 24033923

Group type: EXPERIMENTAL
Intervention: Recombinant C3a/C5a
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pharmacological C5aR blockade
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DC C3a/C5a production lowered by siRNA knockdown of DC C3
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Downregulating DC expression of decay-accelerating factor
Number of subjects: 0
Study: 24034562

Group type: EXPERIMENTAL
Intervention: Carbon ion radiotherapy combined with weekly gemcitabine and adjuvant gemcitabine
Number of subjects: 0
Study: 24035405

Group type: EXPERIMENTAL
Intervention: Tremelimumab 15 mg/kg intravenously once every 90 days until progressive disease or severe toxicity
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Tremelimumab
Number of subjects: 29
Study: 24035447

Group type: EXPERIMENTAL
Intervention: LAP-BAND AP System (LBAP)
Number of subjects: 1106
Study: 24035535

Group type: EXPERIMENTAL
Intervention: Visual cannabis cues
Number of subjects: 16
Study: 24035558

Group type: EXPERIMENTAL
Intervention: In-vitro ring-stage survival assay (RSA) on 0-3 h ring-stage parasites
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ex-vivo RSA
Number of subjects: 30
Study: 24036246

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 0